Electromed Reports 13th Straight Quarter of Revenue and Profit Growth

Electromed Inc. (ELMD) announced it has recorded its 13th consecutive quarter of revenue and net profit growth, with fourth-quarter 2025 revenue reaching $28.4 million, up 12.6% year-over-year. Net income for the quarter totaled $5.1 million, reflecting a 14.3% increase compared to the same period in 2024. This marks the longest streak of sequential profitability and revenue expansion in the company’s history. The growth was driven by increased adoption of its proprietary High-Intensity Respiratory Therapy (HIRT) devices, particularly in outpatient and home care settings. Demand for non-invasive respiratory support solutions has remained strong, supported by rising chronic obstructive pulmonary disease (COPD) prevalence and expanded insurance coverage for at-home medical equipment. ELMD’s gross margin improved to 68.4% in Q4 2025, up from 66.9% in Q4 2024, indicating improved production efficiency and pricing power. The company also reported a 21% year-over-year increase in new patient initiations, signaling strong market penetration. While ELMD remains a mid-cap healthcare stock with a market capitalization under $1.2 billion, its consistent financial performance distinguishes it within the medical devices subsector. The stock’s performance has outpaced both the S&P 500 Health Care Sector ETF (XLV) and the iShares U.S. Health Care ETF (IHF) over the past 12 months, gaining 27% compared to sector averages of 15% and 16%, respectively. Analysts note the company’s disciplined cost management and focus on innovation as key drivers of its sustained growth trajectory.